Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)
Sandra Malak(Institut Curie), Lydia Roy(Centre Hospitalier Universitaire de Poitiers), Jean‐Christophe Ianotto(Inserm), Valérie Ugo(Inserm), Loïc Garçon(Centre Hospitalier Universitaire Amiens-Picardie), Katell Le Dû(Clinique Victor Hugo), Philippe Rodon(Institut d’Hématologie et d’Oncologie Pédiatrique), Pascale Cony‐Makhoul(Hôpital Cardiologique du Haut-Lévêque), Fiorenza Barraco(Hôpital Lyon Sud), Mathieu Wémeau(Inserm), Fabienne Vacheret(Centre Hospitalier de Perpignan), Dana Ranta(Centre Hospitalier Régional et Universitaire de Nancy), François Lefrère(Hôpital Necker-Enfants Malades), Françoise Boyer(Centre Hospitalier Universitaire d'Angers), Jean‐Jacques Kiladjian(Délégation Paris 5)
Cited by 3
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
|Science|2009|1.5k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k